Posted by Michael Wonder on 05 May 2022
Enhertu approved in the US for patients with HER2 positive metastatic breast cancer treated with a prior anti-HER2 based regimen
5 May 2022 - Based on ground-breaking DESTINY-Breast03 results showing Enhertu reduced the risk of disease progression or death by 72% versus trastuzumab emtansine.
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received a prior anti-HER2 based regimen either in the metastatic setting, or in the neo-adjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy.
